
Manufacturing organisations operating under GMP regulations face significant delays and compliance risks due to manual or semi-manual documentation review processes. Batch records, whether paper-based or electronic, require extensive checking for calculation errors, missing entries, transcription mistakes, and regulatory non-compliance. These processes are time-consuming, error-prone, and resource-intensive.
This technology provides a controlled and structured automated documentation review and data verification platform designed to quality check batch records against ALCOA+ principles and GMP requirements. It detects calculation discrepancies, missing data, data limit breaches, transcription errors, time/date inconsistencies, and compliance gaps within a second per page or less. The system works with both paper-based and electronic batch records and produces structured, audit-ready outputs to aid manufacturing teams giving them time back to make more product and it supports QA and QP oversight.
Potential collaborators are pharmaceutical, biotech, cell and gene therapy, and other GMP-regulated manufacturers (cosmetics, FMCG, medtech / device etc) seeking to accelerate batch release, reduce deviations, and improve compliance reliability. The technology addresses a critical market need by reducing review time from days or weeks to minutes, strengthening regulatory compliance, and enabling advanced data trending for continuous process improvement.
The technology consists of:
The platform processes scanned documents (recommended 600dpi) or electronic batch records, applies configurable logic aligned to company SOPs, and generates deterministic compliance reports. It supports hybrid environments transitioning from paper to full electronic systems.
This technology can be deployed across GMP-regulated industries including:
Products and solutions enabled by this technology include:
It can be embedded within existing quality systems to enhance structured review, deviation reduction, audit readiness, and operational excellence initiatives. The technology can also be adopted by other industries that requires reviewing documentation against any set parameters as a quality check e.g. cosmetics, FMCG, aerospace, or use cases outside of manufacturing e.g. distributors in supply chains for reviewal of Certification of Analysis (COAs).
Global pharmaceutical and biologics manufacturing continues to grow, driven by advanced therapies, stricter regulatory enforcement, and increasing data integrity requirements. Regulatory bodies are placing greater emphasis on ALCOA+ principles, data traceability, and inspection readiness. Simultaneously, manufacturers face pressure to reduce operational expenditure while increasing throughput. Manual documentation review remains a bottleneck even in facilities using electronic batch record systems, as many platforms capture data but do not deterministically validate compliance. The market opportunity lies in augmenting existing systems with automated verification and analytics. Independent industry research indicates that digitised, compliant workflows can reduce operational expenditure by up to 30% and increase yield by approximately 10%.
This technology significantly improves upon the current state-of-the-art by introducing automated, deterministic quality checks into documentation workflows that are traditionally manual or semi-manual. It is comparatively easier to implement than a full-fledged Electronic Batch Record System (EBMR), as the document control and data analytics components can be integrated with existing entry processes.
Key value propositions include: